Lunai Bioworks Inc. (LNAI) Stock Price & Analysis
Lunai Bioworks Inc. (LNAI) fell 1.31% to USD 2.26 as of June 11, 2026 at 07:08 UTC, according to Nexqual real-time market data.
LNAI last closed at USD 2.29; the session ranged USD 2.25–2.37 on volume of 26,353 shares. Market capitalization is $10.25M, with a 52-week range of USD 1.21–33.52 (NCM). Source: Nexqual, June 11, 2026 at 07:08 UTC.
Key Statistics (as of June 11, 2026 at 07:08 UTC)
| Price | USD 2.26 |
|---|---|
| Change | ▼ 1.31% (down) |
| Previous Close | USD 2.29 |
| Open | USD 2.25 |
| Day Range | USD 2.25 – 2.37 |
| 52-Week Range | USD 1.21 – 33.52 |
| Volume | 26,353 shares |
| Market Cap | $10.25M |
| Exchange | NCM |
Technical Analysis (LNAI)
Nexqual's technical model rates LNAI "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 11, 2026 at 07:08 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 43.36 (neutral) |
| vs SMA50 | Below (USD 2.63) |
| MACD | -0 (negative) |
Analyst Ratings (LNAI)
Wall Street analysts rate LNAI "None", per Nexqual as of June 11, 2026 at 07:08 UTC.
| Consensus Rating | None |
|---|
Earnings (LNAI)
| Next Earnings Date | 2026-05-15 |
|---|
Source: Nexqual, June 11, 2026 at 07:08 UTC.
Financials & Fundamentals (LNAI)
| Total Revenue | $20,942 |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -6815.30% |
| Profit Margin | +0.00% |
| ROE | -325.46% |
| Current Ratio | 0.19 |
| Total Cash | $3.16M |
| Total Debt | $1.41M |
| Free Cash Flow | $-6.96M |
Source: Nexqual, June 11, 2026 at 07:08 UTC.
Financial Health Score (LNAI)
Nexqual rates Lunai Bioworks Inc.'s overall financial health "Weak" across five dimensions, as of June 11, 2026 at 07:08 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $3M cash vs $1M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$7M, burning cash |
| Efficiency | Critical — ROE -325%, ROA -9.6% |
Ownership (LNAI)
| Insider Ownership | +31.30% |
|---|---|
| Institutional Ownership | +2.76% |
| Shares Outstanding | 4.53M |
| Float | 3.35M |
| Short % of Float | +8.72% |
Source: Nexqual, June 11, 2026 at 07:08 UTC.
Leadership (LNAI)
Lunai Bioworks Inc. is led by David H. Weinstein (age 64), CEO & Director, per Nexqual as of June 11, 2026 at 07:08 UTC.
| CEO & Director | David H. Weinstein (age 64) |
|---|---|
| Chief Financial Officer | Nathen Fuentes (age 42) |
Major Backers & Investors (LNAI)
Notable institutional backers of Lunai Bioworks Inc. include Fidelity, Nine Masts Capital Ltd., Citigroup Inc., according to Nexqual as of June 11, 2026 at 07:08 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.45% |
| Nine Masts Capital Ltd. | 0.28% |
| Citigroup Inc. | 0.28% |
| Virtu Financial LLC | 0.21% |
| Xtx Topco Ltd | 0.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.63% |
| Geode Capital | 0.5% |
| BlackRock | 0.35% |
Source: Nexqual, June 11, 2026 at 07:08 UTC.
From Lunai Bioworks Inc.'s Latest SEC 10-K Filing (filed 2025-09-29)
Key Strengths & Strategy (as disclosed to the SEC)
- Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands.
- It operates through three segments, RENB, BioSymetrics, and RENC.
- The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer.
- It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PFSA | Profusa, Inc. | USD 0.25 | ▼ 15.69% |
| BIYA | Baiya International Group Inc. | USD 1.21 | ▲ 49.75% |
| AZI | Autozi Internet Technology (Glo | USD 2.35 | ▲ 107.96% |
| PAVS | Paranovus Entertainment Technol | USD 0.5 | ▼ 46.87% |
| MASK | 3 E Network Technology Group Lt | USD 3.03 | ▼ 3.81% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 11, 2026 at 07:08 UTC. This page is informational and not investment advice.